A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

NCT06565611 on ClinicalTrials.gov · last registry update 2025-03-06

Closed to new participants; the 108 already enrolled are still being followed. The sponsor logged completion for 5 February 2025. Primary outcome, as filed: Percent change in body weight between treatment arms. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: ACTIVE_NOT_RECRUITING
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: Palatin Technologies, Inc
Sponsor type: Industry
Enrollment: 108
Started: 2024-08-05
Primary completion: 2025-02-05 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent change in body weight between treatment arms

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.